Publication

Exploring new molecular imaging concepts of prostate cancer

Wondergem, M., 2017, [Groningen]: University of Groningen. 208 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and Contents

    Final publisher's version, 223 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 419 KB, PDF document

  • Chapter 3

    Final publisher's version, 5 MB, PDF document

  • Chapter 4

    Final publisher's version, 7 MB, PDF document

  • Chapter 5

    Final publisher's version, 2 MB, PDF document

  • Chapter 6

    Final publisher's version, 3 MB, PDF document

  • Chapter 7

    Final publisher's version, 8 MB, PDF document

  • Intermezzo 1

    Final publisher's version, 3 MB, PDF document

  • Chapter 8

    Final publisher's version, 342 KB, PDF document

  • Summary

    Final publisher's version, 336 KB, PDF document

  • Addenda

    Final publisher's version, 696 KB, PDF document

  • Complete Thesis

    Final publisher's version, 33 MB, PDF document

  • Propositions

    Final publisher's version, 18 KB, PDF document

  • Maurits Wondergem
Prostate cancer is diagnosed in the Netherlands every year in approximately 10,000 new patients and about 2500 patients die each year due to the disease. Imaging techniques play a key role in the staging of the disease and help to make a right choice between the available treatment options. Nuclear medical techniques are used in particular for detecting metastases, of which lymph node metastases and skeletal metastases occur most frequently in prostate cancer patients. Radiopharmaceuticals with proven potential for detecting prostate cancer cells that are investigated in this thesis include: 99mTc-MDP, 99mTc-HDP, NaF, 11C-choline, 18F-fluorocholine and 18F-DCFPyL. By means of a literature study and own data, it became clear that NaF PET/CT and Choline PET/CT are more suitable for detecting skeletal metastases than scintigraphy with 99mTc-MDP or HDP, which has been used for decades. Besides skeletal metastases, soft tissue metastases, for example lymph node metastases, can be detected with Choline or 18F-DCFPyL PET/CT. Various aspects were investigated that could affect the efficacy of these techniques. It became clear that it is of value to scan immediately after administration of Choline and about 45 minutes later. Fasting for several hours before Choline PET/CT has no additional value. Choline PET/CT has little value in the detection of primary lesions or a recurrence in the prostate itself. For 18F-DCFPyL more prostate cancer lesions are seen in 39% of patients at a scan 120 minutes post injection as compared to a scan 60 minutes post injection.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
  • Jong, de, Igle Jan, Supervisor
  • Pruim, Jan, Supervisor
  • van der Zant, Friso M, Co-supervisor, External person
  • Dierckx, Rudi, Assessment committee
  • van Moorselaar, R. J. A., Assessment committee, External person
  • Chiti, Arturo, Assessment committee, External person
Award date20-Nov-2017
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-0160-7
Electronic ISBNs978-94-034-0159-1
Publication statusPublished - 2017

Download statistics

No data available

ID: 49391855